Improving Clinical Outcomes and Patient Satisfaction in Ulcerative Colitis




Provided by Integrity Continuing Education, Inc.


Supported by independent educational grants from AbbVie Inc., Pfizer, Inc., and Takeda Pharmaceuticals U.S.A., Inc.


Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn’s disease (CD), reduces patients’ quality of life and is associated with substantial medical, financial, and social burdens. More than 3 million people in the US and Europe are estimated to have IBD. Despite recent advances in IBD therapies, clinicians are still faced with challenges in treating and managing their patients with UC. Clinicians must choose from a vast array of agents in a variety of drug classes with different mechanisms of action, including agents that are newly available or under clinical investigation. In view of this expansion of therapeutic options, it is crucial for clinicians to remain current regarding all potential treatment strategies to ensure optimal patient outcomes. The individualized needs of specific patient populations, including patients with complex IBD, will be discussed, along with providing multidisciplinary and patient-centered approaches to care.


Anita Afzali, MD, MPH, FACG 
Associate Professor of Medicine
Medical Director, OSU Inflammatory Bowel Disease Center
Abercrombie & Fitch Endowed Chair in Inflammatory Bowel Disease
Division of Gastroenterology, Hepatology and Nutrition
The Ohio State University Wexner Medical Center
Columbus, Ohio

Aline Charabaty, MD, AGAF
Associate Professor of Medicine
Johns Hopkins School of Medicine
Clinical Director, GI Division
Director, IBD Center
Sibley Memorial Hospital
Washington, District of Columbia  

Maia Kayal, MD 
Assistant Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Edward V. Loftus, Jr., MD 
Consultant, Division of Gastroenterology and Hepatology
Professor of Medicine, Mayo Clinic College of Medicine
Co-Director, Advanced Inflammatory Bowel Disease Fellowship
Mayo Clinic
Rochester, Minnesota

Millie Long, MD, MPH 
Associate Professor of Medicine
Director, Gastroenterology and Hepatology Fellowship Program
Vice-Chief for Education
Division of Gastroenterology and Hepatology
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Alan C. Moss, MD 
Professor of Medicine
Boston University School of Medicine
Clinical Director, Crohn’s and Colitis Program
Boston Medical Center
Boston, Massachusetts

Miguel Regueiro, MD 
Chair, Department of Gastroenterology, Hepatology, and Nutrition
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Vice Chair, Digestive Disease Surgery Institute
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Cleveland, Ohio


Release date: February 26, 2021
Expiration date: February 26, 2022
Estimated time to complete activity: 3.75 hour(s)



This program is intended for gastroenterologists, gastroenterologists in training, surgeons, subspecialists including dieticians and psychologists, nurse practitioners, physician assistants, nurses, and other healthcare team members involved in or interested in the care of patients with IBD.


Upon completion of this educational activity, participants should be able to:

  • Apply safety and efficacy data from clinical trials and real-world studies of new and emerging agents to achieve an individualized, patient-centered approach to UC management
  • Interpret the updated UC guidelines to improve treatment decision making and care of patients
  • Evaluate potential approaches for positioning new and emerging therapies for UC
  • Describe clinical situations in which novel therapies may be advantageous for patients with complex IBD

There are no fees for participating and receiving CME credit for this activity. During the period of February 26, 2021 through February 26, 2022 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.




Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 3.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Anita Afzali, MD, MPH, FACG
Consulting Fees: AbbVie, Celgene/Bristol-Myers Squibb, Janssen, Pfizer Inc., Takeda
Speakers’ Bureaus: AbbVie, Janssen, Pfizer Inc., Takeda
Contract Research: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Takeda
Other: IBD Horizons

Aline Charabaty, MD, AGAF
Consulting Fees: AbbVie, Janssen, Takeda
Speakers’ Bureaus: AbbVie, Takeda

Maia Kayal, MD has no real or apparent conflicts of interest to disclose.

Edward V. Loftus, Jr., MD
Consulting Fees: AbbVie, Allergan, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Eli Lilly, Genentech, Gilead, Iterative Scopes, Janssen, Pfizer Inc., Takeda
Contracted Research: AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Gilead, Janssen, Pfizer Inc., Robarts Clinical Trials, Takeda, Theravance

Millie Long, MD, MPH
Consulting Fees: AbbVie, Gilead, Janssen, Pfizer Inc., Prometheus, Takeda, TARGET PharmaSolutions
Contract Research: Pfizer Inc., Takeda

Alan C. Moss, MD
Consulting Fees: Janssen, Pfizer Inc.
Contracted Research: Pfizer Inc.

Miguel Regueiro, MD
Contracted Research: AbbVie, Janssen, Pfizer Inc., Takeda
Consulting Fees/Advisory Boards: AbbVie, Allergan, Amgen, Celgene, Genentech, Gilead, Janssen, Lilly, Miraca Labs, Pfizer Inc., Prometheus, Salix, Seres, Takeda, TARGET PharmaSolutions, UCB
Royalties: Wolters Kluwer Health (Author/Editor of UpToDate)
Unrestricted Educational Grants: AbbVie, Celgene, Genentech, Gilead, Janssen, Pfizer Inc., Takeda, UCB

The Integrity Continuing Education, Inc. planners/managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended.

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below
Click here for more information on minimum system requirements.


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.


Continue to Pretest